Navigation Links
Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Date:4/5/2013

GREENWICH, Conn., April 5, 2013 /PRNewswire/ -- Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics (NVIV), for its recent approvals from the U.S. Food and Drug Administration (FDA). On the heels of FDA approval for Humanitarian Use Device (HUD) designation (an important benchmark and speed-to-market catalyst), InVivo has received yet another important FDA approval – Investigational Device Exemption (IDE), allowing human trials to begin. 

With IDE approval, InVivo will now be able to run first-in-man clinical trials to confirm safety and performance of its biopolymer scaffold. There are currently no treatment options approved by the FDA, or in clinical trials, to intervene directly in the spinal cord following a spinal cord injury. "We believe InVivo's treatment for spinal cord injuries could have a profound impact. If this is approved, it will change lives," said Kevin Kimberlin , Chairman of Spencer Trask & Co. "This is what we are all about – helping entrepreneurs brave enough to work on tough problems, like ending paralysis due to spinal cord injuries."

Spencer Trask Ventures raised $13 million in early-stage funding for InVivo in December of 2010 through its network of individual investors at a share price of $1.00. 

"The funding from Spencer Trask came at a critical time in InVivo's growth – it enabled us to take the next step and expand our facility," said Frank Reynolds , CEO of InVivo Therapeutics. "That was an important milestone for InVivo, and I want to thank those early investors for helping us grow our big idea. These recent FDA approvals take us two giant steps closer to achieving a viable treatment for spinal cord injuries." 

Other

SOURCE Spencer Trask
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
(Date:7/2/2015)... 2, 2015   Decision Resources Group ... identify less frequent dosing as the highest unmet ... the burden on both patients and providers associated ... (VEGF) injections, which are the current standard of ... which is in development for dosing every two ...
(Date:7/2/2015)... , July 2, 2015 ... (Homofermentative & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes ... and Forecast to 2020", Silage Inoculants & Enzymes Market ... a CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
... Sept. 1 There has been recent,concern that ... Montelukast is a Food and Drug Administration (FDA) ... than a decade for the treatment of,asthma and ... the,American Lung Association has found no evidence of ...
... CMS, Inc., an Elekta Company and,worldwide ... management,solutions, today announced that three sites have ... Modulated,Radiotherapy (IMRT) treatment planning system. Allegheny General ... Rotterdam,Netherlands, and Froedtert Memorial Lutheran Hospital in ...
Cached Medicine Technology:American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System 2
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project ... technical sales expertise from the North American Board of Certified Energy Practitioners (NABCEP®), ... most highly respected and well established national certification organization for renewable energy professionals. ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on July 2nd creating a buzz of media attention. In an effort to ... by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... 2015 Annual Conference , the premiere continuing education and networking event ... at SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in ...
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
(Date:7/3/2015)... Lenexa, KS (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... Okla. One of the top-ranked executive search firms in the healthcare industry, B. ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... smoking the first cigarette in the morning, the more difficult ... Yale School of Medicine study in Drug and Alcohol Dependence. ... found significant reductions in craving, withdrawal and mood after smoking ... reduction, the more likely the smoker would relapse, said Benjamin ...
... patients of the superbug MRSA - by treating their foot ... his team used green bottle fly larvae to treat 13 ... found all but one were cured within a mean period ... the conventional treatment. ,Professor Boulton, who published the ...
... developing a brain disease similar to mad cow disease, according ... Academy of Neurology's 59th Annual Meeting in Boston, April 28 ... cow disease, and chronic wasting disease, are fatal and there ... when an animal eats the body parts of other animals ...
... made headway in the development of an investigative blood ... to develop complications in the bone marrow, leading to ... Brisbane's Mater Medical Research Institute (MMRI) and Sydney's West ... a simple blood test to detect such tendencies. ...
... companies is not happy with the proposal to fortify all ... the state and federal governments to veto this proposal. ... enhance the foliate levels in women of child-bearing age. The ... spina bifida. ,If you ask Ian Greenshields from ...
... both get high blood pressure and related kidney disease, the path ... men , researchers say. ,They may end up ... could be very different, says Dr. Jennifer C. Sullivan, pharmacologist/physiologist ... ,Its known that men tend to develop hypertension earlier ...
Cached Medicine News:Health News:Reduction in Nicotine Craving Predicts Ability to Quit 2Health News:Maggots Rid Patients of MRSA 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Cause of Gender Differences in Blood Pressure, Kidney Damage Under Study 2Health News:Cause of Gender Differences in Blood Pressure, Kidney Damage Under Study 3
McIntyre-Binkhorst Cannula have a smooth blunt tip end opening....
Army navy retractor set....
Sharp. 4 mm wide. Hand-Held...
Adsons bayonet forceps....
Medicine Products: